Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
09 Oct 2014 New Study Finds Lack of Adherence to Safe Handling Guidelines for Administration of Antineoplastic Drugs Anticancer agents & Biologic therapy
08 Oct 2014 European Medicines Agency Adopts a Final Negative Opinion for an Extension of Indications for Bevacizumab Central nervous system malignancies - Anticancer agents & Biologic therapy
07 Oct 2014 FDA Expands Approved Use of Ibrutinib for Chronic Lymphocytic Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
06 Oct 2014 ESMO 2014: New Data on First- and Second-Line ALK Inhibition in NSCLC Patients Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
03 Oct 2014 European Medicines Agency Refuses a Change to the Marketing Authorisation for Vinflunine Anticancer agents & Biologic therapy
02 Oct 2014 Rare Cancers Europe Press Release: Specific Clinical Trial Methodology Needed for Rare Cancers
30 Sep 2014 Is precision medicine coming of age? Personalised medicine
30 Sep 2014 ESMO 2014 Wrap-Up: What should be remembered?
30 Sep 2014 Pathway of the Day: PI3K/AKT/mTOR Pathology/Molecular biology
30 Sep 2014 ESMO 2014 Press Release: Cancer Medicine Becoming Ever More Precise, Practice-Changing Results at ESMO 2014 Show
29 Sep 2014 Phase III trial data suggest potential new treatment strategies for prostate cancer Genitourinary cancers
29 Sep 2014 ESMO 2014: Pazopanib Improves Progression-Free Survival in Phase II Study in Patients with Advanced GIST Sarcomas - Anticancer agents & Biologic therapy
29 Sep 2014 ESMO 2014: Cobimetinib in Combination with Vemurafenib Improves PFS in BRAF-Mutant Unresectable Locally-Advanced or Metastatic Melanoma Personalised medicine - Melanoma - Anticancer agents & Biologic therapy
29 Sep 2014 ESMO 2014: Combination Dabrafenib/Trametinib Improves OS in Comparison with Vemurafenib in Patients With BRAF-Mutation Positive Melanoma Personalised medicine - Melanoma - Anticancer agents & Biologic therapy
29 Sep 2014 ESMO 2014: Results of a Phase III Randomised Study of Nivolumab in Patients with Advanced Melanoma After Prior Anti-CTLA4 Therapy Melanoma - Immuno-oncology